Loading...
XSHE300110
Market cap532mUSD
Jan 10, Last price  
3.30CNY
1D
-2.94%
1Q
-3.79%
Jan 2017
-63.21%
IPO
-23.79%
Name

Huaren Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300110 chart
P/E
20.74
P/S
2.38
EPS
0.16
Div Yield, %
2.21%
Shrs. gr., 5y
0.53%
Rev. gr., 5y
3.41%
Revenues
1.64b
+1.04%
161,141,445207,572,968288,546,637338,303,704405,311,965562,034,145867,200,339916,761,3521,105,896,0421,248,972,1981,311,875,3651,383,859,3371,461,940,6241,316,592,2381,560,855,3941,619,492,3351,636,256,356
Net income
188m
+4.03%
34,140,64646,430,66160,766,35276,319,46487,560,91796,587,698121,519,38656,153,98522,936,49823,946,24437,535,03538,794,83742,066,21394,623,997130,404,876180,779,025188,063,014
CFO
306m
+40.19%
7,659,89957,244,29838,627,59777,608,75259,530,88599,442,78339,779,06065,562,08518,766,954181,650,110211,080,360254,316,028309,331,52400217,984,061305,597,473
Dividend
Jul 10, 20240.021 CNY/sh
Earnings
May 16, 2025

Profile

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. The company offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. It also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and carbohydrate metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine solution protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks. In addition, the company offers pharmaceutical packaging materials, including rubber stopper, carton, and membrane; rinsing fluid and API series products; and food and beverage, and medical skin care products. Huaren Pharmaceutical Co., Ltd. was founded in 1998 and is based in Qingdao, China.
URL
https://www.qdhuaren.com/
IPO date
Aug 25, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,636,256
1.04%
1,619,492
3.76%
Cost of revenue
1,136,137
1,218,361
Unusual Expense (Income)
NOPBT
500,119
401,132
NOPBT Margin
30.56%
24.77%
Operating Taxes
37,090
24,521
Tax Rate
7.42%
6.11%
NOPAT
463,029
376,610
Net income
188,063
4.03%
180,779
38.63%
Dividends
(86,146)
(21,274)
Dividend yield
1.73%
0.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
624,828
1,569,675
Long-term debt
836,746
353,557
Deferred revenue
175
721
Other long-term liabilities
2
128,856
Net debt
1,212,946
1,661,264
Cash flow
Cash from operating activities
305,597
217,984
CAPEX
(45,860)
Cash from investing activities
(97,137)
Cash from financing activities
(120,724)
FCF
817,886
307,571
Balance
Cash
232,044
221,707
Long term investments
16,585
40,261
Excess cash
166,815
180,993
Stockholders' equity
2,153,294
2,071,722
Invested Capital
4,060,727
4,393,066
ROIC
10.95%
8.60%
ROCE
11.70%
8.67%
EV
Common stock shares outstanding
1,182,213
1,182,213
Price
4.22
-0.47%
4.24
-11.67%
Market cap
4,988,939
-0.47%
5,012,583
-11.67%
EV
6,273,748
6,742,728
EBITDA
626,971
550,718
EV/EBITDA
10.01
12.24
Interest
65,737
64,161
Interest/NOPBT
13.14%
16.00%